Karyopharm Therapeutics Inc.

As of June 30, 2026, Karyopharm Therapeutics, Inc. carries a market capitalization of 195.05M, placing it among publicly traded companies globally. Its enterprise value stands at 362.31M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Karyopharm Therapeutics, Inc.'s next confirmed earnings release is scheduled for October 29, 2026.

As of June 30, 2026, Karyopharm Therapeutics, Inc. has 22.68M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.30, and the price-to-book ratio stands at -0.67.

These figures are as of June 30, 2026. The EV/Sales ratio of 2.82 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 362.31M versus a market cap of 195.05M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Karyopharm Therapeutics, Inc. maintains a current ratio of 0.79, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -77.59, indicating conservative leverage, while an interest coverage ratio of -1.67 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -207.90, reflecting losses generated across the asset base. The company generates approximately 533,073.15 in revenue per employee across its workforce of 240.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.34 indicates how many times Karyopharm Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Karyopharm Therapeutics, Inc. recorded an income tax benefit of -28,009.60 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -196.74M and -196.71M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

These figures are as of the close on October 22, 2026.

Over the twelve months ended June 30, 2026, Karyopharm Therapeutics, Inc. generated 128.34M in revenue and converted that into -196.71M in net income, yielding earnings per share of -9.81. EBITDA reached -71.95M, while operating income came in at -72.08M.

As of June 30, 2026, Karyopharm Therapeutics, Inc. holds 56.99M in cash and equivalents against 224.24M in total debt, resulting in a net debt position of 170.65M. Total book value stands at -289.00M, with working capital of -24.38M providing operational flexibility.

Karyopharm Therapeutics, Inc. produced -57.20M in operating cash flow over the twelve months ended June 30, 2026. After subtracting - - in capital expenditures, free cash flow totaled -57.20M - equivalent to -2.95 per share.

Over the twelve months ended June 30, 2026, Karyopharm Therapeutics, Inc. posted a gross margin of 95.89, reflecting its pricing power and cost economics. The operating margin of -56.17 and net profit margin of -153.28 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -33.16: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -35.27, meaning Karyopharm Therapeutics, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Karyopharm Therapeutics, Inc.'s most recent stock split took place on February 26, 2025 with a 15:1 split ratio.

As of June 30, 2026, Karyopharm Therapeutics, Inc. has an Altman Z-Score of -24.37, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.